NSPR — InspireMD, Inc.

InspireMD (NSPR) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $2.5 million, a 39% increase year-over-year and over 40% sequential growth.
• U.S. Revenue: $497,000, marking the first quarter of recorded U.S. commercial revenue following FDA approval of CGuard Prime.
• International Revenue: $2.0 million, up 12% from $1.8 million in Q3 2024.
• Gross Profit: Increased to $864,000 (over 100% increase) from $414,000 in Q3 2024.
• Gross Margin: Improved to 34.2% from 22.9% year-over-year.
• Operating Expenses: Increased to $13.9 million, up 57% from $8.9 million in Q3 2024, primarily due to increased headcount and infrastructure costs.
• Net Loss: $12.7 million, or $0.17 per share, compared to a net loss of $7.9 million, or $0.16 per share in Q3 2024.
• Cash Position: $63.4 million as of September 30, 2025, significantly up from $19.4 million at the end of Q2 2025, bolstered by a PIPE offering and milestone-based financing.

2. Strategic Updates and Business Highlights

• CGuard Prime Launch: Strong early momentum in the U.S. market, with over 100 procedures completed. The device is gaining traction among major integrated delivery networks (IDNs).
• Market Positioning: CGuard Prime is positioned as a workhorse stent, aiming to be widely adopted due to its clinical efficacy and competitive pricing strategy.
• Clinical Trials: Ongoing studies, including C-GUARDIANS II and III, are expected to enhance the product's market reach and clinical validation.
• Leadership Addition: Dr. Peter Soukas appointed as Chief Medical Officer to strengthen clinical and medical oversight.

3. Forward Guidance and Outlook

• Q4 2025 Revenue Guidance: Expected to be between $2.5 million and $3.0 million, with anticipated growth in U.S. sales and stable international demand.
• Long-Term Growth: Confidence in sustainable growth driven by market penetration and ongoing clinical studies, with further insights into 2026 growth expectations to be shared in the next earnings report.

4. Bad News, Challenges, or Points of Concern

• Operating Losses: The significant net loss reflects ongoing investment in commercial expansion and infrastructure, raising concerns about the sustainability of current spending levels.
• High Operating Expenses: Increased costs associated with expanding the U.S. commercial team and establishing headquarters may pressure future profitability.
• Market Competition: The carotid intervention market is competitive, and the company must continue to demonstrate superior clinical outcomes to maintain and grow market share.

5. Notable Q&A Insights

• Physician Feedback: Positive initial feedback on CGuard Prime, with physicians appreciating its dual capabilities in various anatomical scenarios.
• Sales Strategy: The company is focusing on hands-on support during initial cases to ensure proper utilization before transitioning to broader distribution.
• Sales Force Expansion: Plans to grow the U.S. commercial organization to over 30 personnel by year-end, with a focus on customer-facing roles to drive market penetration.
• Product Ordering Trends: Initial orders are modest, with physicians starting with a few units and gradually increasing as they gain confidence in the product's performance.
• Gross Margin Expectations: Anticipated improvement in gross margins as U.S. sales grow, with expectations to reach typical medical device margins over time.

This summary encapsulates the key points from InspireMD's Q3 2025 earnings call, highlighting both the progress made and the challenges ahead as the company seeks to establish itself in the carotid intervention market.